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Objective: To assess the in vitro susceptibility of clinical isolates to cefepime and five other antimicrobial agents with 
broad-spectrum activity. 
Methods: The minimal inhibitory concentrations of 1521 Gram-positive cocci and 3170 Gram-negative rods were 
determined by the Etest procedure. 
Results: The susceptibilities were as follows. Gram-positive bacteria: cefepime, 92.7%; ceftazidime, 60.5%; ceftriaxone, 
87.8%; imipenem, 92.6%; amikacin, 56.5%; ciprofloxacin, 72.5%. Gram-negative bacteria: cefepime, 97.8%; ceftazidime, 
94.3%; ceftriaxone, 83.1%; imipenem, 95.7%; amikacin, 96.6%; ciprofloxacin, 95.8%. 
Conclusions: Cefepime had the best activity when compared with the other broad-spectrum p-lactams ceftazidime, 
ceftriaxone, imipenem, and the non-p-lactams amikacin and ciprofloxacin. 
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INTRODUCTION MATERIALS AND METHODS 
Cefepime is a fourth-generation cephalosporin with an 
expanded spectrum including both Gram-negative and 
Gram-positive organisms. This compound is resistant to 
hydrolysis by a variety of p-lactamases, even those with 
extended activity, e.g. extended TEM P-lactamases, 
with the exception of TEM-3, TEM-9 and p-lactamases 
of Morganella [l]. In general, cefepime has an activity 
that is similar to or exceeds that of third-generation 
cephalosporins for most commonly isolated human 
pathogens. It is particularly more active than the latter 
against multiresistant Enferobacferiaceae, such as group 1 
cephalosporinase-producing strains [2,3]. 
Shortly before its introduction, a multicenter study 
encompassing 26 hospitals in Switzerland was per- 
formed to assess the in vitro susceptibility of clinical 
isolates to cefepime and five other antimicrobial agents 
with broad-spectrum activity. 
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Bacterial strains 
Between September 1994 and March 1995, each 
hospital laboratory was requested to collect 520  strains 
of each species or group of species up to a total of 1220 
consecutive and non-repetitive aerobically growing 
bacterial isolates per center. Enterococci were excluded 
because of their intrinsic resistance to cephalosporins 
[l]. Only strains from patients admitted to the hospitals 
were collected. Clinical specimens allowed were blood, 
urine, sputum, tracheal secretion, bronchoalveolar lavage 
fluid, pus including trauma discharge, and punctures. 
*Participating hospitals or laboratories: Burgerspital Solothurn, 
CHUV Lausanne, HBpital Cantonal Universitaire de GenPve, 
Hbpital de Zone de DelCmont, HBpital de Zone de Morges, HBpital 
de Zone de Vevey, Hygienisch-Mikrobiologisches Institut Aarau, 
Institut Central des HBpitaux Valaisans Sion. Institut cantonal 
d'hygisne et de microbiologie Fribourg, InstiNt &r Klinische 
Mikrobiologie und Immunologie St Gallen, Institut fur Medizinische 
Mikrobiologie Bern, Institut Neuchitelois de Microbiologie La- 
Chaux-de-Fonds, Kantonsspital Basel, Kantonsspital Frauenfeld, 
Kantonsspital Luzern, Kantonsspital Munsterlingen, Kantonsspital 
Olten, Kantonsspital Schafthausen, Kantonsspital Winterthur, 
Kantonsspital Zug, Kinderspital Zurich, Ospedale Civic0 Lugano, 
Ospedale San Giovanni Lugano, Rhatisches Kantons- und 
Regionalspital Chur, Triemlispital Zurich, Universititsspital Zurich. 
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Identification was performed in each laboratory by its 
routine methods. 
Susceptibility testing 
Susceptibility testing was performed according to a 
standardized procedure in each laboratory: minimal 
inhibitory concentrations (MICs) of cefepime, cef- 
tazidime, ceftriaxone, imipenem, amikacin, and cipro- 
floxacin were determined by the Etest procedure (AB 
Biodisk, Solna, Sweden) [4]. For staphylococci, the 
MIC of oxacillin was also determined. Inoculum pre- 
paration and choice of media followed the US National 
Committee for Clinical Laboratory Standards (NCCLS) 
guidelines for disk susceptibility testing [5]. Mueller- 
Hinton agar plates (14 cm in diameter) were used for 
non-fastidious bacteria. Streptococci, including 
Streptococcus pneumoniae, were tested on Mueller- 
Hinton agar supplemented with 5% sheep blood, and 
Haemophilus spp. on Haemophilus Test Medium (HTM). 
For detection of methicillin-resistant staphylococci, 
2% NaCl was added to Mueller-Hinton agar for 
determining the MIC of oxacillin. Six Etest strips were 
added to the inoculated plates according to the 
manufacturer's written procedures. 
Concentrations tested and breakpoints for suscept- 
ibility are listed in Table 1; they follow the guidelines 
set by NCCLS standard M7-A3 [6]. With the 
exception of ceftriaxone for testing pneumococci (0.5 
mg/L instead of 0.25 mg/L), these breakpoints have 
not changed in the latest NCCLS supplement [7]. The 
following quality control strains were included: 
Escherichia coli American Type Culture Collection 
(ATCC) 25922, Pseudomonas aeruginosa ATCC 27853, 
Haemophilus injuenzae ATCC 49247, Staphylococcus 
aureus ATCC 29213, and Streptococcus pneumoniae 
ATCC 49619. The results of quality control had to be 
sent to the trial monitor at Bristol-Myers Squibb, Baar, 
Switzerland, who worked in close collaboration with 
the bacteriology laboratory at the Kantonsspital Basel. 
Seventy-one isolates resistant to cefepime for which 
sensitivity might be expected were sent to the Basel 
laboratory for confirmation. The retesting confirmed 
the categorical results of 67 (94.4 %) isolates with MICs 
within the range of *I dilution in 65 (91.5%). 
Considering the high rate of agreement, the original 
test results were not altered. Evaluation of data was 
performed by Dr  Lorenzo Hess, Brunner & Hess 
Software, Zurich, Switzerland. 
One  thousand five hundred and twenty-one Gram- 
positive and 31 70 Gram-negative bacterial strains were 
collected and tested. The overviews in Tables 2 and 3, 
respectively, show the susceptibilities of Gram-positive 
and Gram-negative organisms according to species. 
Table 4 gives a summary of the overall susceptibility of 
Gram-positive and Gram-negative organisms. 
Cefepime was, in general, more active than the 
other p-lactams tested. As was to be expected, its activity 
was also insufficient against methicillin-resistant staphy- 
lococci, which have to be considered as resistant to all 
p-lactams [5,7]. Amikacin and ciprofloxacin had limited 
activity against many Gram-positive cocci as well. 
As examples, Figures 1 and 2 plot the MIC values 
of cefepime versus those of ceftazidime for Enterobacter 
cloacae and Pseudomonas aeruginosa, respectively. Whereas 
a number of Enterobactev cloacae strains susceptible to 
cefepime were resistant to ceftazidime, there was almost 
complete cross-sensitivity among the Pseudomonas 
aeruginosa isolates, which is reflected by the percentage 
of susceptible strains in Table 3. 
In comparison with other p-lactam antibiotics 
tested, cefepime was the most active, even compared 
with imipenem. The non-related representatives of 
the aminoglycosides and quinolones, amikacin and 
Table 1 Concentration range for MIC determination and breakpoints for definition of susceptibility [6]. 
Breakpoint (mg/L) 
Antimicrobial Concentration Streptococcus Haemophilus 
agent range (mg/L) Au" pneumoniae SPP. 
Cefepime 0.016-256 5 8  50.25 5 2  
Ceftazidime 0.016-256 5 8  ~ 0 . 2 5 ~  5 2  
Ceftriaxone 0.016-256 5 8  50.25 5 2  
Imipenem 0.002-32 5 4  sn.12 5 4  
Amikacin 0.016-256 5 1 6  NA' NA' 
Ciprofloxacin 0.002-32 1 1  NA' NA' 
'Applicable to all isolates with the exception of Streptococcus pneumoniue and Huemophilus spp. 
bThe NCCLS does not give a breakpoint for ceftazidime and pneumococci; the breakpoint has been chosen by analogy with other 
cephalosporins. 
'No specific breakpoints are defined by the NCCLS. 
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Table 2 Activity of cefepime compared with other antitiiicrobial agents against Gram-positivc cocci 
~~ 
Organism Antimicrubial 
(no. of isolates) agent (mg/L) (mg/L) (~iig/L) 
Staphybrorrus aurcus 
(nirthicillin susceptible) 
(468) 
Staph ylococrus aunw 
(niethicillin resistant) 
(32y 
Coaylase-negative 
staphylococci 
(niethicillin susceptible) 
(250) 
Coabalasc-negative 
staphylococci 
(niethicillin resistant) 
(154)^ 
Streptococcus pneurnoniae 
(312) 
Srrq~tororcrrrs o,valacriar 
(106) 
Othcr streptococci 
(73) (rnterococci 
excluded)" 
Cefepinir 
Ceftazidinir 
Ceftriaxone 
Iniipenern 
Aniikacin 
Ciprofloxacin 
Crfrpinir 
Ceftazidinie 
Ceftriaxone 
tniipeneni 
Ainikacin 
Ciprofloxacin 
Cefepime 
Ceftazidirne 
Cefiriaxonr 
lniipenem 
Aniikacin 
Ciprofloxacin 
Crfepinie 
Ceftazidinie 
Ceftriaxone 
liniprnem 
Aniikacin 
Ciprofloxacin 
Cefepinie 
Ceftazidime 
Ceftriaxone 
Iiniprneni 
Aniikacin 
Ciprofloxacin 
Cefepimr 
Ceftazidinie 
Ceftriaxonr 
Irnipmem 
Aniikacin 
Ciprofloxacin 
Crfrpinic 
Ceftazidimc 
Ceftriaxone 
Irnipenrni 
Aniikacin 
Ciprofloxacm 
Crfrpiine 
Crftazidmme 
Crftriaxonr 
tniiprncni 
Ainikacin 
Ciprofloxaciii 
0.017 to X 
0.047 to 32 
0.19 to 32 
0.1)12 to >32 
0.  I9 to >?SO 
10.01)l to 2 
0.1)32 to 32 
( I .  125 to  >250 
0.016 to 128 
0.002 to >32 
O.l)h4 to 32 
0.016 to >32 
1O.Olb to 2 
O.(Ih4 to 4 
~0.1116 to 0.3u 
~ 1 l . 0 0 1  to 0.7.5 
0.000 to >32 
1 to >256 
l l . l I l 0  to 16 
11.19 to Oh 
l l . ( I l O  to 12 
l).004 to I .5 
0.38 to x 
24 t o  >25h 
2 
12 
1.5 
0.023 
3 
0.25 
>250 
>250 
>25h 
12 
>32 
2.25 
0.75 
6 
1.5 
( I  , I  )S2 
1.5 
0. I9 
8 
06 
32 
32 
12 
8 
O.ll32 
(1.25 
0.016 
lI.IIOX 
00 
1 
0.1)23 
11.25 
0.023 
0.(112 
0.75 
128 
O.lI04 
1 
lI.ll64 
0.047 
1 
>25(1 
11.5 
0 
11.25 
ll.Il47 
1.5 
00 
,'According to thc NCCLS. nirthicillin-resistant stqihvlococu have to be rondcrcd  'is rcsistaiit ag~inrt dl p-lxtaiiis. dc\pite in vitro 
susceptibility 15.71. 
'This group comprises the Strcptococcus niilleri group .I\ well 3s or;il strcptococ-ci. 
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Table 3 Activity of cefepime compared with other  antimicrobial agents against Gram-negative bacteria 
- 
MICm MICro Susceptible 
(mg/L) strains (%) 
Organism 
(no. of isolates) 
Antimicrobial MIC range 
agent (mg/L) 
Kkbsiella pnenmoniae 
(3'4) 
Errterobacter cloacae 
(255) 
Enterobacter aeropner 
(37) 
Enterobacter spp. 
(other) 
(36) 
Protens mirabilis 
(294) 
Protens vulpris 
(153) 
Morganella morganii 
(129) 
Providencia retgeri 
(13) 
Escherichia roli Cefepime 
(547) Ceftazidime 
Cefiriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Cefiriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
50.016 to 24 
0.023 to >256 
50.016 to 32 
0.012 to 32 
0.004 to >32 
0.75 to >256 
50.016 to 6 
0.032 to >256 
50.016 to >256 
0.004 to 2 
0.064 to 48 
0.003 to >32 
50.016 to 2 
0.047 to 1.5 
50.016 to 32 
0.094 to 3 
0.5 to 8 
0.004 to 24 
50.016 to 12 
0.047 to >256 
50.016 to >256 
0.023 to 12 
0.064 to 12 
0.003 to >32 
0.032 to 4 
0.094 to >256 
0.047 to 2256 
0.125 to 32 
0.75 to 4 
0.012 to 0.5 
0.047 to 2 
0.064 to >256 
0.016 to >256 
0.125 to 4 
0.5 to 6 
0.006 to 32 
50.016 to 6 
0.016 to 8 
10.016 to >256 
50.001 to 16 
0.064 to 16 
0.012 to >32 
50.016 to 3 
0.016 to 0.25 
50.016 to >256 
0.023 to >32 
0.047 to 12 
0.008 to 0.5 
50.016 to 1 
50.016 to >256 
50.016 to >256 
0.19 to 32 
0.5 to 16 
0.002 to >32 
50.016 to 0.064 
0.047 to 0.25 
50.016 to 0.023 
0.5 to 3 
1 to 3 
0.008 to 0.19 
0.047 
0.38 
0.047 
0.19 
2 
0.023 
0.047 
0.25 
0.047 
0.25 
0.064 
0.047 
0.19 
0.064 
0.25 
2 
0.032 
0.064 
0.5 
0.25 
0.25 
2 
0.023 
0.064 
0.5 
0.125 
2 
0.032 
0.047 
0.5 
0.125 
0.38 
2 
0.064 
0.064 
0.094 
50.01 6 
0.38 
2 
0.023 
0.064 
0.094 
0.023 
0.75 
2 
0.032 
0.032 
0.19 
0.016 
2 
2 
0.016 
0.023 
0.064 
50.016 
1 
2 
0.023 
7 
I 
0.38 
0.125 
0.75 
0.125 
0.25 
3 
0.064 
0.19 
1 
0.25 
0.38 
3 
0.25 
0.125 
0.5 
0.315 
0.38 
3 
0.094 
1 
96 
128 
0.75 
3 
0.094 
1 
.256 
64 
1.5 
3 
0.064 
1.5 
4 
24 
1.5 
4 
0.5 
0.125 
0.25 
0.016 
2 
6 
0.064 
0.19 
0.25 
0.38 
4 
3 
0.047 
0.064 
2 
0.38 
8 
4 
0.047 
0.032 
0.125 
0.016 
1.5 
3 
0.125 
99.6 
99.1 
99.6 
99.8 
99.5 
98.0 
100 
96.9 
97.2 
98.8 
98.8 
100 
100 
100 
100 
100 
99.3 
99.3 
99.6 
82.7 
81.2 
99.6 
99.2 
100 
100 
83.8 
83.8 
94.6 
100 
100 
100 
94.5 
94.4 
100 
100 
97.2 
100 
100 
98.6 
98.3 
98.6 
ion 
100 
100 
96.1 
94.8 
100 
100 
100 
93.0 
99.2 
77.5 
99.2 
100 
100 
100 
100 
100 
100 
100 
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Table 3 (continued) 
~~~ ~ 
Organism Antimcrobial MIC range MICso MICs" Suscephble 
(no of isolates) agent (mg/L) (mg/L) (mg/L) strains (%) 
Citrobacter fieundii 
(123) 
Citrobacter diversus 
(86) 
Serratia spp 
(128) 
Salmonella spp. 
(25) 
Pseudomonas aeruginosa 
(440) 
Acinetobacter baumannii 
(37) 
Acinetobacter spp. 
(other) 
(56) 
Stenotrophomonas maltophilia 
(32) 
Haemophifrrs spp 
(304)' 
Cefepime 
Cefiazidime 
Cefiriaxone 
Imipenem 
Amikacin 
ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Cefiazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidirne 
Cefiriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepinie 
Ceftazidnne 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Cefiriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Ceftriaxone 
Imipenern 
Amikacin 
Ciprofloxacin 
Cefepime 
Cefiazidime 
Cehriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
Cefepime 
Ceftazidime 
Cefiriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
0.016 to 4 
0.125 to >256 
0.016 to >256 
0.032 to 3 
1 to 12 
0.004 to 16 
50.016 to 0.19 
0.094 to 1.5 
0.016 to 0.38 
0.094 to 0.75 
0.5 to 6 
0.002 to 32 
0.016 to 0.19 
0.047 to 64 
0.047 to 16 
0.125 to 4 
1 to96 
0.004 to 12 
0.047 to 0.125 
0.064 to 0.125 
0.125 to 4 
1 to 4 
0.016 to 0.19 
0.38 to 1 
0.023 to >256 
0.125 to >256 
50.016 to 2256 
0.023 to >32 
0.19 to >256 
0.012 to >32 
0.047 to 16 
0.25 to 96 
0.064 to >256 
0.064 to 3 
0.38 to 24 
0.032 to >32 
0.064 to 128 
0.75 to 96 
0.047 to >256 
0.003 to >32 
0.38 to 32 
0.047 to >32 
1.5 to 128 
0.75 to >256 
3 to >256 
0.38 to >32 
3 to >256 
0.19 to >32 
50.016 to >256 
10.016 to >256 
50.016 to >256 
50.001 to >32 
50.001 to 8 
3 to 24 
0.047 
0.75 
0.19 
0.38 
2 
0.023 
0.032 
0.25 
0.047 
0.19 
1.5 
0.012 
0.125 
0.38 
0.25 
0.38 
3 
0.125 
0.094 
0.5 
0.094 
0.38 
0.047 
1.5 
3 
3 - 
16 
1.5 
4 
0.19 
2 
6 
12 
0.25 
2 
0.25 
4 
6 
16 
0.25 
0.25 
3 
1 
24 
>256 
>32 
32 
0.75 
1.5 
0.064 
0.125 
S0.016 
0.5 
8 
0.012 
0.75 
256 
64 
0.75 
3 
0.19 
0.094 
0.75 
0.19 
0.25 
3 
0.064 
0.25 
0.75 
0.75 
0.75 
6 
0.25 
0.125 
0.75 
0.125 
3 
0.064 
8 
6 
>256 
6 
12 
2 
8 
8 
32 
0.38 
3 
0.75 
8 
16 
32 
0.5 
6 
4 
48 
>256 
>256 
>32 
>256 
8 
0.19 
0.25 
50.016 
1.5 
24 
0.032 
0.75 
100 
76.4 
78.9 
100 
100 
99.2 
100 
100 
100 
I00 
100 
98.8 
100 
98.4 
99.2 
99.2 
96.9 
100 
100 
100 
100 
100 
100 
100 
93.6 
93.2 
25.1 
89.1 
93.6 
85.4 
94.6 
91.9 
27.0 
97.3 
91.9 
92.9 
82.5 
31.6 
96.5 
94.7 
86.0 
31.3 
45.9 
3.1 
3.1 
37.5 
43.8 
99.0 
96.7 
99.0 
97.4 
88.8 
99.0 
100 
'284 Haemophilus iniuenrae and 20 other Haemophilus spp. 
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Table 4 Summary of activity of cefepime compared with other antimicrobial agents. 
Organism Antimicrobial MIC range MICso MICw Susceptible 
(no. of isolates) agent (mg/L) ( W L )  (mg/L) strains ("h) 
Gram-positive cocci Cefepime 
(1521) Ceftazidime 
Crfiriaxonc 
Imipenem 
Amikdcin 
Ci profloxscin 
Gram-negmve rods Cefepime 
(3170) Cefiazidime 
Ceftriaxone 
Imipenem 
Amikacin 
Ciprofloxacin 
0.015 to >256 
0.015 to >256 
0.01.5 to >256 
0.001 to >32 
0.047 to >256 
0.001 to >32 
0.75 
6 
0.75 
0.023 
h 
0.5 
0.064 
0.3x 
0.064 
0.25 
0.032 
7 
I 
7 - 
3 
24 
2 
8 
0.25 
92.7 
60.5 
87.8 
92.6 
56.5 
72.5 
97.x 
94.3 
83.1 
95.7 
96.6 
95.8 
1- 
0- 1.000 
0 c/ 
O a  
- 1- 
-2. 0.135 I 
9 
- 57 
-5 -4 
0.135 1.000 
-3 - 2  -1  0 
__ 
1 
I I 
I 
I 
I 
I I 
I 
I ! 
I I 
I 
I 1 
7.289 54.59 
2 3 4 5 
In MIC Cefepime 
(MlC 8: breakpoint sensitive) 
(MIC 32: breakpoint resistant) 
Figure 1 Cross-resistance of Enterobactev clourue against cefepime and ceftazichme (N= 255). 
ciprofloxacin, also showed good activity. All antimicro- 
bial agents had poor activity against Stetzotvophomonas 
vnaltophilia. 
O f  the p-lactams tested, ceftazidime had the poor- 
est activity against pneumococci. This was to a large 
part due to the low breakpoint chosen for susceptibility, 
by analogy with cefepime and ceftriaxone. Thirty- 
three per cent of pneumococci fell into the inter- 
mediate range for ceftazidime, and only 3.1% were 
resistant, with an MIC 1 2  mg/L. For cefepime and 
ceftriaxone, the number of Streptococcus pneumoniae 
strains having an MIC 2 3  mg/L were two (0.6%) and 
one (0.3%), respectively; three strains (1%) had an MIC 
of imipenem 2 1 mg/L. It has to be stated that ceftri- 
axone, cefotaxime and imipenem are the therapies of 
choice for severe infections with penicillin-resistant 
pneumococci [8]. Cefepime may be an alternative to 
these proposed p-lactams [9]. 
DlSCUSSlON 
Cefepime is a zwitterionic C-3' quaternary ammon- 
ium cephalosporin belonging to the fourth-generation 
cephalosporins according to its structural and anti- 
bacterial characteristics [10,11]. Cefepime combines 
the excellent activity of the third-generation cephalo- 
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Figure 2 Cross-resistance of Pseudoinonas aeruginosa against cefepime and ceftazidime (N=440). 
sporins against Gram-negative organisms with the high 
activity of the first-generation cephalosporins against 
Gram-positive organisms [ 1,121. 
As the study shows, cefepime had the best activity 
when compared with the p-lactams cefiazidime, ceftri- 
axone, imipenem, and the non-B-lactams amikacin and 
ciprofloxacin. In contrast to its excellent activity against 
Enterobacteriaceae and good activity against Pseudo- 
monas aeruginosa, the activity of cefepime was poor 
against the nosocomial Gram-negative bacteria natur- 
ally resistant to most p-lactam antibiotics, such as 
Acinetobacter spp. and Stenotrophomonas maltophilia. It also 
showed the expected poor activity against methicillin- 
resistant staphylococci of all species. In contrast to the 
third-generation cephalosporin cefiazidime, it had 
excellent activity against staphylococci susceptible to 
methicillin. 
This study was an in vitro investigation and did not 
address clinical efficacy. This has to be proven in clinical 
trials. 
In conclusion, cefepime has an extended spectrum 
superior to that of third-generation cephalosporins 
against Gram-negative bacteria, mainly due to its 
activity against derepressed mutants [2,13], a much 
better activity, comparable to that of first-generation 
cephalosporins, against staphylococci, and an activity 
equal to that of cefiriaxone against pneumococci. This 
study shows the potential of cefepime in nosocomial 
infections, mainly in intensive care units, due to the 
higher prevalence of resistant bacteria in this setting 
[14,15]. The development of resistance, however, has 
to be carefully monitored. 
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